RELEVANT TRIALS: MOBILITY, TARGET
ACR20 clinical response was observed in MTX-IR and TNF-IR patients as early as 2 weeks in MOBILITY and as quickly as 4 weeks in TARGET, respectively, after the first dose.1
KEVZARA provided patients with uncontrolled RA
fast, lasting clinical improvement1
OF MTX-IR PATIENTS MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENT IN PHYSICAL FUNCTION THROUGH WEEK 52 WITH KEVZARA 200 mg + MTX3*
Week 16: KEVZARA 200 mg + MTX: 57% (229/399) vs placebo + MTX: 42% (169/398);
Week 52: KEVZARA 200 mg + MTX: 48% (190/399) vs placebo + MTX: 26% (104/398)
56% OF MTX-IR PATIENTS HAD NO RADIOGRAPHIC PROGRESSION WITH KEVZARA AT 52 WEEKS vs 39% OF PATIENTS TREATED WITH PLACEBO2*
greater inhibition of joint damage progression
with KEVZARA 200 mg + MTX vs placebo + MTX2
DMARDs=disease-modifying antirheumatic drugs; ALT=alanine aminotransferase; ANC=absolute neutrophil count; GI=gastrointestinal.
Reference: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc.